ALNYLAM PHARMACEUTICALS, INC. (33) | Uncategorized (12)
Recent Contracts
-
Letter Agreement between the Registrant and
(Filed With SEC on April 28, 2022)
-
Letter Agreement effective as of October 26, 2021 between the Company and John M. Maraganore, Ph.D
(Filed With SEC on October 28, 2021)
-
Letter Agreement between the Registrant and Laurie B. Keating dated September 6, 2021
(Filed With SEC on October 28, 2021)
-
Sponsored Research Agreement dated as of July 27, 2009 by and among the
(Filed With SEC on August 3, 2021)
-
Amendment No. 1 to Sponsored Research Agreement dated as of July 27, 2009
(Filed With SEC on August 3, 2021)
-
Supplemental Agreement effective July 27, 2009 by and among the
(Filed With SEC on August 3, 2021)
-
Co-Development Agreement between the Registrant and BXLS
(Filed With SEC on November 5, 2020)
-
First Amendment to
(Filed With SEC on November 5, 2020)
-
Letter Agreement between the Registrant and Barry E. Greene dated August 26, 2020
(Filed With SEC on November 5, 2020)
-
Patent Cross-License Agreement dated April 3, 2020 between Dicerna Pharmaceuticals, Inc. and the Registrant
(Filed With SEC on August 6, 2020)
-
Investor Agreement dated as of April 8, 2019 by and between the Registrant and Regeneron Pharmaceuticals, Inc
(Filed With SEC on August 6, 2019)
-
Amended and Restated Investor Agreement dated as of April 8, 2019 by and between the Registrant and Genzyme Corporation
(Filed With SEC on August 6, 2019)